Semaglutide prescribing information explained: approved doses for Ozempic, Wegovy, and Rybelsus, boxed warnings, side effects, and where to find the label.
The semaglutide prescribing information is the FDA-approved package insert for Ozempic, Wegovy, and Rybelsus, and it is the same document a clinician reads before writing a prescription. It lists approved uses, starting and maintenance doses, contraindications, the boxed warning, and the side effects reported in clinical trials. Because regulators and manufacturers update it whenever new safety data appears, the package insert is a far better source than social media posts or secondhand pharmacy talk.
What the Semaglutide Package Insert Contains
Every version of the semaglutide package insert follows the 17-section format the FDA requires for prescription drugs. That structure lets you skip straight to the section you actually need.
- Indications and usage: the exact conditions each product is approved to treat.
- Dosage and administration: starting dose, titration steps, missed-dose rules, and the labeled maximum dose.
- Contraindications: the patients who should never receive the drug.
- Warnings and precautions: pancreatitis, gallbladder disease, acute kidney injury from dehydration, low blood sugar when combined with insulin or sulfonylureas, and diabetic retinopathy complications.
- Adverse reactions: rates of nausea, vomiting, diarrhea, constipation, and other events seen in trials.
- Drug interactions, specific populations, and storage: including refrigeration ranges and in-use limits for pens.
The label is a clinical and legal document rather than marketing copy. Manufacturers revise it as trial data and safety signals accumulate, so the revision date printed in the header matters as much as the text itself.
Approved Forms of Semaglutide and Standard Dosing
Semaglutide is sold under three brand names in the United States, and each one has its own approved dose range. A dose that is standard for one product is not automatically approved for another.
| Product | Form | Approved use | Starting dose | Maintenance and maximum dose |
|---|---|---|---|---|
| Ozempic | Weekly injection (pen) | Type 2 diabetes, reduced risk of major cardiovascular events, chronic kidney disease in type 2 diabetes | 0.25 mg once weekly for 4 weeks | 0.5 mg to 2 mg weekly; maximum 2 mg |
| Wegovy | Weekly injection (single-dose pen) | Chronic weight management; reduced cardiovascular risk in adults with obesity and heart disease | 0.25 mg once weekly for 4 weeks | 2.4 mg weekly; maximum 2.4 mg |
| Rybelsus | Oral tablet | Type 2 diabetes | 3 mg once daily for 30 days | 7 mg daily, may increase to 14 mg; maximum 14 mg |
Dose escalation and missed doses
Semaglutide is titrated slowly to limit gastrointestinal upset. Ozempic typically moves from 0.25 mg to 0.5 mg, then 1 mg, then 2 mg, with at least four weeks at each step. Wegovy follows a longer ladder: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg.
Missed-dose instructions differ by product. Ozempic can be taken within five days of the missed dose; if more than five days have passed, that dose is skipped. Wegovy should be taken within two days when the next scheduled dose is more than two days away. Rybelsus users skip the missed tablet and resume the following morning.
Boxed Warning and Contraindications
All semaglutide products carry a boxed warning about thyroid C-cell tumors observed in rodents during studies. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
Known hypersensitivity to semaglutide or its inactive ingredients is also a contraindication. Semaglutide is not recommended during pregnancy, and Wegovy should be discontinued at least two months before a planned pregnancy because the drug clears slowly from the body.
Semaglutide is not approved for use in pregnancy, and people with a history of medullary thyroid cancer or MEN2 should not take it.
Semaglutide Side Effects and How Long They Last
Gastrointestinal symptoms dominate the adverse reaction profile, and they are the most common reason people stop treatment. Most events are mild to moderate and cluster around dose increases.
| Adverse reaction | Typical frequency in trials | Practical note |
|---|---|---|
| Nausea | Very common | Peaks during titration and usually fades |
| Vomiting, diarrhea, constipation | Common | Stay hydrated; report persistent vomiting |
| Abdominal pain | Common | Severe upper abdominal pain needs medical review |
| Hypoglycemia | Mainly with insulin or sulfonylureas | May require adjusting those medications |
| Injection site reactions | Common | Rotate injection sites weekly |
| Gallbladder disease, pancreatitis, acute kidney injury | Uncommon but serious | Seek care for severe pain or dehydration |
Patients often ask how long do semaglutide side effects last, and the pattern in the label is fairly consistent. Symptoms tend to ease within a few weeks once the dose is held steady, though some people need a slower titration or a temporary step back down.
If digestive symptoms last beyond several weeks, get worse, or come with signs of dehydration, contact a healthcare professional. Persistent vomiting and severe abdominal pain can point to pancreatitis, gallbladder problems, or kidney injury, all of which are listed in the warnings section.
What the Prescribing Information Does Not Cover
Compounded semaglutide is not described in any FDA-approved label. Compounded products are not reviewed for safety, effectiveness, or accurate dosing, and the FDA has issued warnings about dosing errors tied to them.
Combination research also sits outside the label. Cagrilintide and semaglutide are being studied together as a dual-hormone therapy, and the cagrilintide semaglutide dosage used in those trials is experimental rather than approved for routine prescribing.
Stacking retatrutide and semaglutide is another practice with no prescribing information behind it. Retatrutide remains investigational, and combining two drugs that act on overlapping appetite pathways can stack side effects without any proven added benefit.
Where to Find the Most Current Label
The National Library of Medicine maintains the DailyMed database, which hosts the latest FDA-approved labeling for Ozempic, Wegovy, and Rybelsus. Manufacturer websites also publish the full package insert as a PDF, usually next to a plain-language medication guide.
Key Takeaways
- The semaglutide prescribing information is the authoritative source for approved uses, doses, and safety warnings.
- Labeled maximum doses differ by product: 2 mg weekly for Ozempic, 2.4 mg weekly for Wegovy, and 14 mg daily for Rybelsus.
- A boxed warning for thyroid C-cell tumors and a contraindication for medullary thyroid cancer or MEN2 apply to every semaglutide product.
- Nausea, vomiting, and diarrhea are the most common side effects and typically improve within weeks of a stable dose.
- Compounded semaglutide and unapproved drug combinations are not covered by any FDA-approved label.
Frequently Asked Questions
Is semaglutide FDA-approved for weight loss?
Wegovy, which is semaglutide 2.4 mg, is FDA-approved for chronic weight management in adults with obesity or excess weight plus a related health condition, and for adolescents 12 and older. Ozempic and Rybelsus are approved for type 2 diabetes, not for weight loss. Using them for weight loss is an off-label decision a prescriber may make.
What is the maximum dose of semaglutide?
The labeled maximum is 2 mg once weekly for Ozempic, 2.4 mg once weekly for Wegovy, and 14 mg once daily for Rybelsus. Doses above those limits are not supported by the FDA-approved prescribing information. Anyone considering a higher dose should discuss it with a healthcare professional rather than adjusting on their own.
How long do semaglutide side effects usually last?
Nausea, vomiting, diarrhea, and constipation most often peak during dose increases and improve within days to a few weeks once the dose is stable. Some people need a slower titration schedule to stay comfortable. Symptoms that persist for more than a few weeks or include severe abdominal pain, persistent vomiting, or dehydration should be evaluated by a clinician.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.